Related Experiment Video
Updated: Jul 15, 2026
Creation of a Knee Joint-on-a-Chip for Modeling Joint Diseases and Testing Drugs
Published on: January 27, 2023
Combating Inflammation and Promoting Anabolism in Osteoarthritic Cartilage Defect With an MMP13-Sensing Dual-Drug
Zhen Zhang1, Bangheng Liu2,3, Yulei Mu1
1Department of Biomedical Engineering, City University of Hong Kong, Kowloon, Hong Kong SAR, China.
Abstract:
Osteoarthritis (OA) is a widespread degenerative joint condition marked by progressive cartilage breakdown, and a chronic inflammatory microenvironment, where conventional therapies largely fail to halt disease progression. To address this unmet need, an intra-articularly implantable, disease-responsive scaffold was developed for combinatorial treatment to simultaneously combat inflammation and promote anabolism. The system is based on an MMP13-sensing peptide-modified type II collagen scaffold engineered for controlled release of celecoxib (CXB), an anti-inflammatory agent, and fibroblast growth factor-18 (FGF-18), a pro-anabolic growth factor. Comprehensive physicochemical characterization confirmed the scaffold's porous structure, successful conjugation of the responsive peptide, and MMP13-dependent drug release. In vitro studies demonstrated excellent biocompatibility, potent anti-inflammatory effects, and enhanced chondrogenic matrix production under IL-1β stimulation. When evaluated the rat OA cartilage defect model, the dual-drug scaffold significantly suppressed inflammation and subchondral bone damage, while promoting early matrix anabolism, and outperforming the control group. This MMP13-sensing scaffold represents a precision medicine strategy for OA therapy, enabling intelligent, microenvironment-driven drug delivery to disrupt the degenerative cycle and facilitate synergistic early-stage anti-inflammatory and anabolic effects.
Insights
A novel osteoarthritis scaffold releases anti-inflammatory and growth drugs in response to disease markers. This precision medicine approach combats inflammation and promotes cartilage repair, offering a new therapy for osteoarthritis.
Area of Science:
- Biomaterials Science
- Regenerative Medicine
- Drug Delivery Systems
Background:
- Osteoarthritis (OA) involves cartilage breakdown and inflammation, with current treatments often failing to halt progression.
- There is a significant unmet need for therapies that can simultaneously address inflammation and promote tissue regeneration in OA.
Purpose of the Study:
- To develop an implantable, disease-responsive scaffold for combinatorial OA treatment.
- To engineer a scaffold for controlled release of celecoxib (anti-inflammatory) and FGF-18 (pro-anabolic) based on MMP13 sensing.
Main Methods:
- Type II collagen scaffold modified with MMP13-sensing peptides for controlled drug release.
- In vitro evaluation of biocompatibility, anti-inflammatory effects, and chondrogenic matrix production.
- In vivo assessment in a rat OA cartilage defect model.
Main Results:
- Scaffold demonstrated porous structure, peptide conjugation, and MMP13-dependent drug release.
- In vitro studies showed biocompatibility, potent anti-inflammatory action, and enhanced matrix production.
- In vivo, the scaffold suppressed inflammation, reduced bone damage, and promoted anabolism in OA models.
Conclusions:
- The MMP13-sensing scaffold enables precision medicine for OA by delivering drugs based on the microenvironment.
- This intelligent system disrupts the degenerative cycle by combining early-stage anti-inflammatory and anabolic effects.
- The developed scaffold shows promise for a synergistic therapeutic strategy in osteoarthritis treatment.
